Oasmia Pharmaceutical AB Stock Company Profile
Information
Vallongatan 1
Uppsala 752 28
46 18 50 54 40
www.oasmia.com
Description
Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The companys approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.